Next Generation Sequencing Disease Panels
Helping you transform complex cases into clear solutions
Cancer is a complex disease that varies from individual to individual. GenomeMe’s Next Generation Sequencing panels enable quick identification of all the mutations within complex pathways that result in a cancer phenotype. Solve complex cases faster and make big breakthroughs in the fight against cancer with GenomeMe’s Next Generation Sequencing panels.
Solid TumorsTarget clinically relevant solid tumor-associated genes
Tumor Actionable MutationsTargets exonic regions of 8 solid-tumor-associated genes that contain variants of clinically actionable significance, as determined by medical organizations such as NCCN, CAP, and ASCO. Our NGS services provide high coverage, specificity, and reproducibility, critical for detecting variants of low-frequency from samples.
Clinically Relevant TumorTarget regions of 24 genes that are clinically relevant for the prognosis and diagnosis of solid tumor-associated genes, as identified by medical groups such as NCCN, CAP, and ASCO. Includes full coverage of the coding regions of certain oncogenes as well as tumor suppressor genes where any mutations may have functional importance.
Hematologic MalignancyTarget tumor suppressor genes strongly associated with human myeloid leukemia
Myeloid NeoplasmsTargets the most relevant exonic regions of 50 oncogenes and tumor suppressor genes strongly associated with human myeloid leukemia. Genes in this panel include receptor tyrosine kinases FLT3 or KIT (linked with acute myeloid leukemia) as well as TP53 or RB1 (linked with chronic myeloid leukemia).
Disease SpecificTarget sets of genes clinically relevant to specific cancer types
Breast CancerA heterogenous cancer composed of various tumor subtypes that each have their own mechanism of carcinogenesis. This panel includes point mutations in PIK3CA as well as other genes whose mutations are most relevant to breast cancer.
Colorectal CancerIncidences of colorectal cancer are on the rise, particularly in older patients, however colorectal cancer is treatable in its early stages.
Liver CancerLiver cancer includes hepatocellular carcinoma (the most common form of liver cancer) as well as cholangiocarcioma (or bile duct cancer), two subtypes of cancer that share similarities in their molecular mechanisms of carcinogenesis.
Lung CancerThis panel includes genes strongly associated with the two major subtypes of lung cancer: small-cell lung carcinoma and non-small-cell lung carcinoma.
Ovarian CancerBecause it is usually diagnosed in its later stages, the mortality rate of ovarian cancer is higher than any other gynecological cancer.
Prostate CancerMany mutations can lead to the oncogenic development of cancer in the male reproductive tissues, making prostate cancer one with a high mortality rate. This panel targets 32 genes associated with prostate cancer.
Gastric CancerGastric cancer includes the cancers of the esophagus, liver, lungs, and lymph nodes, with many of the associated mutations as yet unidentified. This panel targets exonic regions of 29 genes strongly associated with gastric cancer.
CardiomyopathyThis panel targets coding regions of 58 genes commonly mutated in hereditary cardiomyopathy as based on OMIM, Clincar, and dbSNP databases.
Comprehensive CancerThis panel targets hundreds of genes linked to cancer and X-linked disorders
Carrier TestingEnables parents to find out whether they carry recessive forms of pathogenic mutations that may be passed down to their children. Targets 157 genes associated with 123 autosomal or X-linked inherited disorders of which there is a 5 in 1 million chance of inheriting.
Cancer PredispositionThis panel targets exonic regions of 143 genes from heritable diseases associated with 88 different inheritable cancers, as determined by OMIM, ClinVar, dbSNP, and the Familial Cancer databases. Includes heritable diseases that leads to cancer in 50% of those that are affected.
Comprehensive CancerThe genome of a tumor may evolve as it progresses, resulting in an increased number of rare mutations. Target exonic regions of 160 genes, including genes from 8 of our individual cancer panels that are commonly mutated in various cancers.
Gene-SpecificTarget key genes known to be markers for specific cancer types
Gastric CancerBRCA genes are crucial markers of ovarian cancer, with germline and somatic mutations the target of various therapies such as a class of drugs called PARP inhibitors. Our panel is optimized to sequence BRCA1 and BRCA2 genes from blood and FFPE samples.